Echosens
Capucine Chambard has extensive work experience in various roles and industries. Their most recent position is as the Global Pharma Partnerships Director at Echosens, where they lead efforts to position the company as the diagnostic partner of choice for pharmaceutical companies. Prior to this, they served as a Member of the Investment Committee at LUTECH, assessing the market fit of healthtech innovation for investment decisions. Capucine also held the role of Head of Global Marketing - Business Development at Diabeloop and Global Marketing Director at MicroPort CRM. Capucine has worked at Merck as a Marketing Director and Digital Transformation Leader in the Diabetes & Cardiovascular division, as well as a Healthcare Solutions Manager for hospitals. Capucine Chambard's earlier experience includes roles as a Healthcare Consulting Practice Leader at Publicis Healthcare Consulting / Insync, Marketing Director EMEA - Interventional at GE Healthcare, and Global Product Group Manager at GE Consumer Industrial. Capucine began their career as a Consulting Manager at Arthur Andersen Business Consulting, working on projects in customer relationship management and growth strategies across various industries.
Capucine Chambard earned their Executive Master's degree in "Management & Public Health Policy" from Sciences Po from 2017 to 2019. Before that, they pursued a DEA degree in Marketing & Strategy at Université Paris Dauphine - PSL in 1996-1997. Prior to their DEA degree, Capucine attended NEOMA Business School, although specific details regarding their degree and field of study are not provided.
Additionally, Capucine Chambard obtained a certification as a Lean Six Sigma Black Belt from GE Healthcare, although no information is available regarding the month or year of completion.
Echosens
1 followers
A pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is recognized worldwide as the reference for liver fibrosis and liver steatosis assessment with more than 4,200+ peer-reviewed publications and 180+ international guidelines recommendations. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. We are working hand in hand with physicians, medical academic research, pharmaceutical companies for patient identification and monitoring in NAFLD/NASH. As patient education is a major issue, we have created the "myliverexam" website that provides information about the role of the liver and why it is vital to the global health.